返回
Medicenna Therapeutics Corp（MDNAF）价格
MDNAF 股价走势图
MDNAF 收益
Medicenna Therapeutics Corp
$0.65
-5.5%
$-0.03
收盘价：Jan 26, 16:00:00 GMT-5
$0.68
4.61%
$0.03
盘后：Jan 26, 20:00:00 GMT-5
关键数据
前收盘价
$0.6879
开盘价
$0.6755
当日区间
$0.6401 - $0.6917
52周范围
$0.573 - $1.43
交易量
38.0K
平均成交量
134.3K
每股收益（TTM）
-0.12
股息收益率
--
市值
$56.7M
什么是 Medicenna Therapeutics Corp.？
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.